LAVA Therapeutics (LVTX) News Today → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free LVTX Stock Alerts $2.71 -0.12 (-4.24%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financialsmarkets.businessinsider.com - March 25 at 2:46 AMLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Resultsfinance.yahoo.com - March 20 at 9:17 AMLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Resultsglobenewswire.com - March 20 at 7:00 AMLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)finanznachrichten.de - March 6 at 6:45 PMLava gets $7M from Pfizer as trial for cancer drug advancesmsn.com - March 5 at 10:44 AMLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)globenewswire.com - March 5 at 7:30 AMLAVA Therapeutics (NASDAQ:LVTX) Trading Up 37.7%marketbeat.com - March 5 at 5:06 AMAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)markets.businessinsider.com - March 1 at 9:35 AMLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest Reportbenzinga.com - February 21 at 4:27 PMLAVA Therapeutics NV (LVTX)investing.com - February 14 at 3:12 PMLava signs collaboration agreement with MSD for prostate cancer therapymsn.com - January 25 at 8:11 PMPCSA, ONCO and KAVL among mid-day moversseekingalpha.com - January 25 at 3:11 PMLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®finance.yahoo.com - January 25 at 10:11 AMLAVA Therapeutics N.V. (LVTX)ca.finance.yahoo.com - December 13 at 8:17 AMLAVA Therapeutics NV LVTXmorningstar.com - November 11 at 10:20 AMLava Therapeutics is latest life sciences company to trim its workforcebizjournals.com - August 25 at 3:39 PMLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 22 at 9:28 AMLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 22 at 9:28 AMLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34msn.com - July 6 at 8:59 PMLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runwayfinanznachrichten.de - June 14 at 1:02 PMLava Therapeutics shelves hematology drug over competitive concernsmsn.com - June 14 at 1:02 PMHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy Recommendationmsn.com - June 12 at 5:49 PMJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)markets.businessinsider.com - June 9 at 1:23 AMLAVA Therapeutics to Participate in the Jefferies Healthcare Conferencefinance.yahoo.com - June 1 at 10:23 AMLAVA Announces Annual Meeting of Shareholdersfinance.yahoo.com - May 30 at 8:35 PMIs a Beat Likely for Cooper Companies (COO) in Q2 Earnings?uk.finance.yahoo.com - May 30 at 10:34 AMLAVA Therapeutics Stock (NASDAQ:LVTX), Dividendsbenzinga.com - April 17 at 6:23 PMJMP Securities Sticks to Its Buy Rating for LAVA Therapeutics (LVTX)markets.businessinsider.com - April 12 at 2:35 AMLAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Resultsfinance.yahoo.com - April 11 at 9:54 AMLAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directorsfinance.yahoo.com - March 9 at 8:55 AMLAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposiumfinance.yahoo.com - February 16 at 9:45 AMLAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 9 at 7:58 AMLAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical Officermarkets.businessinsider.com - February 6 at 10:57 AMLAVA Therapeutics (NASDAQ:LVTX) Sees Significant Drop in Short Interestmarketbeat.com - January 27 at 10:12 PMLVTX LAVA Therapeutics N.V.seekingalpha.com - January 26 at 3:23 PMLAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposiumfinance.yahoo.com - January 23 at 8:59 AMLAVA Therapeutics Announces Appointment of New Directors to the Boardfinance.yahoo.com - January 6 at 1:40 PMLAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 7:11 AMLAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Expositionfinance.yahoo.com - December 10 at 4:14 PMWill LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Knowfinance.yahoo.com - November 14 at 1:23 PMLAVA Therapeutics to Present at the Jefferies London Healthcare Conferencefinance.yahoo.com - November 4 at 3:33 PMLAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Expositionfinance.yahoo.com - November 3 at 1:20 PMLAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officerfinance.yahoo.com - November 1 at 8:00 AMLAVA Therapeutics: Assessing A Promising Innovatorseekingalpha.com - October 18 at 3:10 AMLAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meetingfinance.yahoo.com - October 7 at 3:12 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), LAVA Therapeutics (LVTX) and Design Therapeutics (DSGN)markets.businessinsider.com - September 28 at 7:14 AM5 Analyst Price Target Changes of Noteza.investing.com - September 26 at 7:51 PMLAVA Therapeutics Skyrockets After Cancer Agreement With Seagenfinance.yahoo.com - September 26 at 2:50 PMSeagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223markets.businessinsider.com - September 26 at 9:41 AMSeagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumorsfinance.yahoo.com - September 26 at 9:41 AM Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget NVIDIA, buy this $2 AI stock now… (Ad)This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract. Click here to learn more >>> LVTX Media Mentions By Week LVTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LVTX News Sentiment▼0.000.52▲Average Medical News Sentiment LVTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LVTX Articles This Week▼00▲LVTX Articles Average Week Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Context Therapeutics News Grifols News Mainz Biomed News Pharvaris News Tiziana Life Sciences News Aclarion News Alpha Tau Medical News American Oncology Network News Artelo Biosciences News bioAffinity Technologies News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LVTX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchThe #1 Crypto for 2024InvestorPlaceYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.